aimsco

What aimsco does

Aimsco Limited is a privately held UK pharmaceutical company, registered in England and Wales (Reg no. 04836207) and headquartered at 3 Beeston Place, Belgravia, London, that owns all intellectual property rights to AIMSPRO®, a biological therapy derived from caprine (goat) hyper-immune serum. The product was fully developed, initially produced, and tested with assistance from a major US university in 1999. Aimsco holds 10 patent families covering manufacturing process, composition of matter, and defined mechanism of action, with 84 patents granted internationally and additional applications pending across jurisdictions including major European countries, USA, Canada, New Zealand, and Australia. The IP estate also includes trademarks registered in multiple jurisdictions.

AIMSPRO® is positioned as a disease-arresting biological therapy for multiple neurological and autoimmune indications. Pre-clinical and clinical studies report tolerability and safety in a long-term study of more than 150 MS patients, a 21-patient ALS study, multi-patient case studies in Alzheimer's Disease (showing stabilization and reversal), and accelerated chronic wound healing versus standard practice. A Phase II double-blind placebo-controlled trial in diffuse systemic sclerosis was published in the British Medical Journal, and the company cites additional work in COVID-19 immune response and cytokine storm in Nature and New Scientist. Regulatory authorizations include a UK MHRA manufacturer's specials licence (2005), Australian TGA Specials Access Scheme approval under categories A and B (2007), FDA Orphan Drug designation for ALS (2009) and Systemic Sclerosis (2013), and TGA Orphan Drug status for Krabbe's Disease (2005) and ALS (2009).

The business operates on a compassionate use model: doctors in the UK and Australia are authorized to prescribe AIMSPRO® directly to qualifying patients through special access schemes rather than through standard commercial sales channels. Pricing is not publicly disclosed. The company has no disclosed institutional investors, funding rounds, executive team, or headcount. In 2016, Aimsco revoked a Patent License previously granted to Daval International under clause 6.2.2, citing breach due to acts and omissions, reclaiming direct commercialization rights. The company is currently operational with an active website and investor contact channel but presents as a small, privately financed specialty biologics developer.

Name

aimsco

Legal name

Aimsco Limited

Website

https://aimsco.co.uk

Company type

Private

Founded year

1999

Operating status

Operating

Short description

Aimsco Limited is a privately held UK pharmaceutical company that owns AIMSPRO®, a biological therapy derived from caprine hyper-immune serum, prescribed on a compassionate use basis for neurological and autoimmune conditions including Multiple Sclerosis, ALS, and Alzheimer's Disease.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industries

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Biological therapy products
• Hyper-immune serum treatments
• Orphan drug development
• Rare disease therapeutics
• Compassionate use pharmaceuticals

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Distribution channels2 records

Marketing channels1 record

Core offering

Aimsco Limited develops and owns AIMSPRO®, a proprietary biological therapy derived from caprine (goat) hyper-immune serum. The therapy has demonstrated disease-arresting capabilities across Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Krabbe's Leucodystrophy, Systemic Sclerosis, and chronic wounds. The product is prescribed on a compassionate use basis under regulatory approvals in the UK (MHRA Manufacturer's Specials Licence, 2005) and Australia (TGA Specials Access Scheme, 2007), and holds Orphan Drug designations from the FDA and TGA for multiple indications.

Product overview

Aimsco Limited offers a single core biological product, AIMSPRO®, a therapy derived from caprine hyper-immune serum. The treatment has been developed for multiple disease indications including Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Krabbe's Disease, Alzheimer's Disease, and chronic wound healing. The product represents the entirety of the company's pharmaceutical portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• AIMSPRO®: A biological product derived from a caprine hyper-immune serum source, administered as a unique biological therapy for diseases including Multiple Sclerosis, Krabbe's Leucodistrophy, Amyotrophic Lateral Sclerosis, and Alzheimer's Disease.

Products and services

• AIMSPRO® AIMSPRO® is a biological therapy derived from caprine hyper-immune serum, prescribed on a compassionate use basis by doctors under MHRA (UK) and TGA (Australia) regulatory approvals. It is indicated for Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Krabbe's Leucodystrophy, Systemic Sclerosis, and chronic wounds. The product has confirmed disease-arresting capability in pre-clinical (in vitro and in vivo) and clinical studies, with tolerability and safety confirmed in a 21-patient ALS study and a long-term study of more than 150 MS patients.

Quantifiable outcome

• Tolerability and safety confirmed in 21-patient study for ALS and long-term study of 150+ MS patients
• +2 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AB Science: French biopharma developing masitinib for ALS and systemic sclerosis/mastocytosis; directly comparable in both ALS and systemic sclerosis indications where Aimsco has orphan designations.
• Biogen: Major neurological-disease biopharma with multiple sclerosis, ALS (e.g., tofersen) and Alzheimer's programs, directly overlapping with AIMSPRO's primary indication focus on MS, ALS and Alzheimer's.
• Mitsubishi Tanabe Pharma: Developer of edaravone/Radicava for ALS, the only widely approved disease-modifying ALS therapy; directly comparable in the ALS indication where Aimsco holds FDA Orphan Drug designation.
• Cytokinetics: Clinical-stage company developing muscle-activator therapies for ALS and other neuromuscular diseases; comparable as a focused, indication-aligned rare neurological biopharma.
• Ionis Pharmaceuticals: Antisense-based platform developing therapies for rare neurological diseases including ALS and spinal muscular atrophy; comparable as a rare neurological biologics developer with multi-indication orphan strategy.
• Alnylam Pharmaceuticals: RNAi platform company with multiple rare-disease orphan-drug approvals (e.g., Onpattro, Givlaari); comparable as a multi-indication rare-disease biologics developer leveraging orphan exclusivity.
• BioMarin Pharmaceutical: Specialty rare-disease biopharma with multiple orphan-drug products across neurological and metabolic rare conditions; comparable as a multi-orphan rare-disease commercial-stage biologics developer.

Broad incumbents

• Sanofi (Genzyme): Large biopharma with deep rare-disease franchise (Genzyme) including multiple sclerosis (Lemtrada, Aubagio); broad incumbent with overlapping neurological/autoimmune rare-disease capabilities.
• Roche: Major biopharma with leading MS franchise (Ocrevus) and active Alzheimer's pipeline; broad incumbent with significant overlap in the neurological indications Aimsco targets.
• Teva Pharmaceutical: Large generics/specialty biopharma with multiple MS products (Copaxone) and CNS franchise; broad incumbent competing in Aimsco's primary MS indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about aimsco